Ophthalmology, Surger, Seha Abodhabi, UAE
*Corresponding Author: Bashir Alnajjar,Ophthalmology, Surger, Seha Abodhabi, UAE.
Received: January 31, 2020; Published: February 27, 2020
Thyroid eye disease (TED) is seen most commonly with Graves’ disease Symptoms include diplopia, eyelid erythema and retraction, and soreness and grittiness of eyes with increased watering. Severe cases (3 - 5%) may present with pain, corneal ulceration, optic nerve compression and partial/total loss of vision.
Corticosteroids are the primary treatment for active phase TED, although there is risk of adverse effects such as weight gain, hypertension and immunosuppression with long-term, high-dose use.
We will discuss a patient history with TED before, during and after treatment with tocilizumab and steroids Tocilizumab is current treatment options for moderate-to-severe.
Given the role in the pathogenesis of TED of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory is that inhibition of IL-6 by tocilizumab may be an effective treatment in TED by directly reducing the inflammatory response.
Keywords: Thyroid; Eye Disease
Citation: Bashir Alnajjar. “Thyroid Eye Disease (Ted) Management: A Case Report”. Acta Scientific Ophthalmology 3.2 (2020): 40-44.
Copyright: © 2020 Bashir Alnajjar. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.